Company Analysis
Sign in

Anbio Biotechnology (NNNN)

Nasdaq: NNNN · In Vitro & In Vivo Diagnostic Substances · Frankfurt Am Main, DE · filing with the SEC since 2023
Full chart Alerts Compare
Grade5.7
◀ Past 4.4● Present 6.1▶ Future 6.3
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$8.6M+5.6%
Net income$6.4M+169.9%
Earnings per share$0.15+162.5%
Operating cash flow-$6.7M-423.9%
Cash$7.8M-34.0%
Debtn/a
Shareholders’ equity$30.2M+75.4%
Shares, diluted43.7M+3.3%
Return on equity21.2%
The recordfrom its filings
Filings in 202614
Newest filingJul 9 · F-3ASR
Annual reportApr 7, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
22232425
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton NNNN · research, not advice